Replicel Life Sciences Inc.

Haarige Angelegenheit....

Eine Firma mit Sitz in Canada unter deutscher Leitung
ISIN: CA76027P1036  WKN: A1JHCB

Zellbasiertes Verfahren – innovative Behandlung von Haarausfall

Ein international renommiertes Haarforscherteam unter medizinischer Leitung Prof. Dr. Hoffmann, Universität Marburg, hat ein neuartiges Verfahren zur Behandlung vom erblich bedingten Haarausfall entwickelt. Diese Methode ermöglicht nach Forscherangaben eine dauerhafte Lösung gegen Haarausfall. Dabei können sowohl Männer als auch Frauen davon profitieren.

Ein riesiger Markt könnte entstehen!
Replicel hat eine Zusammenarbeit mit Shiseido begonnen und einen Rahmenvertrag über den Transfer von technischen Entwicklungen bezüglich einer exklusiven geografischen Linzenz für RepliCels RCH-01 Haarregenerationstechnologie abgeschlossen.

Shiseido ist eines der ältesten und angesehensten Kosmetikunternehmen der Welt mit jährlichen Verkaufszahlen von über 6,7 Milliarden US-Dollar.

http://www.replicel.com/  

Haarausfall ist ein schweres Schicksal – Jetzt macht eine neue Behandlungsmethode Mut

Interview mit dem wissenschaftlichen Vorstand von RepliCel Prof. Dr. R. Hoffmann

http://www.wallstreet-online.de/nachricht/...l-behandlungsmethode-mut

 

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 09/06/13 -- RepliCel Life Sciences Inc. (OTCBB: REPCF)(CNSX: RP), a clinical stage biopharmaceutical company focused on the development of autologous cell therapies, announces that pursuant to its Stock Option Plan, the Company granted 1,310,000 options to various employees and consultants of the Company. The options vest over a three year period and are exercisable at $0.55 per share until September 5, 2020.

http://www.finanznachrichten.de/...nounces-stock-option-grant-256.htm  

Kurzes Video zur Zelltherapie von Replicel

 

Zusätzlich arbeitet Replicel auch an Verfahren zur Sehnenrekonstruktion.

 

Ist noch jemand von euch hier bei RepliCel investiert? Der Kurs ist nun wieder auf ansehlich tiefem Niveau unten. Ist das nun ein Invest wert, hat die Firma Aussicht auf eine Zukunft? Wie schätzt ihr das ein?

P.S. Die Gener8 Aktie kam auch schön runter und ist nun wieder massiv gestiegen, das hätte ein ganzes Jahr Börse erspart, inklusive News- und Wirtschaftsinfo lesen zu müssen. Wenn man sich nur trauen würde....hmmm.  

Sieht richtig billig aus. Bin jetzt mal drin.

RepliCel Life Sciences: Patienten-Rekrutierung für klinische Sehnenrekonstruktions- und Hautverjüngungsstudien abgeschlossen

Ergebnisse beider Studien werden Kommerzialisierungsaktivitäten, Partner-Gespräche und weitere klinische Entwicklungen unterstützen

VANCOUVER (BRITISH COLUMBIA), 20. April 2016 - RepliCel Life Sciences Inc. (Frankfurt: P6P1); OTCQB: REPCF; TSX-V: RP), ein Unternehmen für regenerative Medizin, das sich im klinischen Stadium befindet und auf die Entwicklung autologer Zelltherapien fokussiert ist, meldete heute, dass es seine letzten Patienten für seine klinischen RCT-01- und RCS-01-Studien rekrutiert hat. Dadurch wird sichergestellt, dass klinische Daten beider Studien analysiert und vor Jahresende veröffentlicht werden können. Positive Sicherheitsdaten werden es dem Unternehmen ermöglichen, im Jahr 2017 mit Phase-2-Studien für beide Produkte fortzufahren. Daten hinsichtlich der Wirksamkeit der Produkte nach der Injektion werden die Grundlage für die Produktentwicklung des Unternehmens sowie für die Strategie der klinischen Studien sowohl für die Sehnenrekonstruktions- als auch für die Hautverjüngungsanwendungen darstellen.
...

Ergebnisse also Ende des Jahres.  

fetter Rebound gestern! ;-)  

...Im Januar sollten ja die Ergebnisse von Shisheido reinkommen. Hoffentlich passt das, dann startet die Rakete ansonsten wirds ein Rohrkrepierer ;-)  

http://www.cantechletter.com/2017/01/...buckler-talks-cantech-letter/  

http://us5.campaign-archive2.com/...mp;id=21bc67a33f&e=c892204d88
 

rollt langsam los, Ergebnisse kommen in Kürze rein :-)  

...der Zug rollt langsam los, bitte alle einsteigen ;-)

Haarausfall:
http://www.fiercebiotech.com/biotech/...herapy-safe-glimmers-efficacy

Methode scheint sicher, an der Effektivität muss noch gearbeitet werden.

Sehnen:
http://www.newswire.ca/news-releases/...endon-problems-617271903.html

Methode scheint sicher, Optimierungen i.B.

Haut:
http://www.prnewswire.com/news-releases/...ing-to-date-618101633.html

Methode scheint sicher, regeneratives Potential anscheinend sehr hoch :-)

Na denn jetzt sollte es doch up gehen - hoffen wir es werden bald Deals gemeldet dann fliegt der Deckel.

Greetz  

 







United States Patent Issued to RepliCel for its Novel Dermal Injection Technologies

With exclusive U.S. rights to RCI-02 patents, RepliCel edges its nearest-term commercial asset closer to launch in large aesthetic market


VANCOUVER, BC – April 25, 2017 - RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel” or the “Company”), a clinical stage regenerative medicine company developing cell therapies for aesthetic and orthopedic conditions, today announced the granting of a key patent in the United States (U.S. Patent No. 9,616,182) covering significant components of the Company’s novel, multi-needle dermal injection device.

In the development of propriety cell therapy products targeting pattern baldness (androgenetic alopecia) and aging or sun-damaged skin, RepliCel’s dermatology team identified a need for next-generation dermal injection techologies capable of bringing new levels of precision and control to any substances injected into the skin.  

The patent issued by the U.S. Patent and Trademark Office (USPTO) relates to technologies designed to  enable both unparalleled control and repeatable consistency of needle action and product deposition. The patent also relates to the element designed to numb the skin prior to injection with the intended effect of reducing, if not eliminating, the need for local anesthetic prior to aesthetic injection procedures.

The first device being developed under this patent, RCI-02, is designed for injecting soft tissue fillers such as hyaluronic acid (“HA”). According to recent statistics released by the American Society for Plastic Surgery (April 2017), there were over 11 million minimally invasive cosmetic procedures performed nationally in 2016: over 80% were wrinkle treatments and hyaluronic acid filler injections, totalling an expenditure of over $3 billion.1 RCI-02 represents the nearest-term commercial opportunity for the Company, which it intends to have market-ready and in the hands of a co-development licensee and commercial partner next year (2018).  

The device is also being developed for the injection of RepliCel’s RCH-01 hair restoration and RCS-01 skin rejuvenation products. Future iterations of the device will be optimized for other injectables such as drugs, biologics, vaccines, fat grafts, etc.

The U.S. patent adds to the Company’s intellectual property portfolio, which includes two European patents for RCI-02, both granted February 9, 2017. RepliCel’s first European patent for its injection technologies (Patent No. 2623146) was validated in a total of fourteen countries, including Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Spain, Switzerland, Sweden and the United Kingdom.  The second European Patent (No. 2809381) is now being validated in a number of European countries and is expected to be complete in the near future.

“We are confident RepliCel’s extensive patent estate for its cell therapy and injection devices will provide our products with long-term market exclusivity,” said Lee R. Buckler, CEO of RepliCel.  “The granting of this U.S. patent is an important addition to RepliCel’s formidable intellectual property portfolio, which we believe will further build value for our investors.”

“Exclusive U.S. rights to the world’s largest aesthetic medical device market represents a significant opportunity for the Company as it addresses an unmet need in the cosmetic dermal injection market,” said Dr. Rolf Hoffmann, RepliCel’s Chief Medical Officer, a practicing dermatologist and the primary inventor of the RCI-02 injector. “Single needle syringes available today do not have the ability to precisely deliver dermal fillers with predictable and consistent results,” he stated.

Dr. Hoffmann continued by saying, “RepliCel’s RCI-02 injector has been designed to provide unprecedented reliability, reproducibility, and programmability of three-dimensional skin injections, enabling clinicians better control and consistency, while also providing less-experienced injection specialists with the confidence to undertake these procedures with desired outcomes.”

“The Company is on track to have prototypes ready in Q3 2017 for initial functional and usability testing by engineers, as well as, user-groups,” continued Mr. Buckler.  “This year is about building and testing commercial-grade prototypes. Next year, our goal is to get RCI-02 CE-marked, licensed to a commercial partner and generating revenue.”

About RCI-02
The RCI-02 injector was designed with input from dermatologists, industrial designers, and electronic and medical device engineers to improve the delivery of a variety of injectables in a controlled, precise manner, removing the risks and uncertainties of injection outcomes currently resulting from manually operated, single-needle syringes.  

RCI-02 is the world’s first motorized injection device with programmable depth and volume, a built-in Peltier element for pre-injection anaesthetising and interchangeable needle head configurations. It is designed to deliver a variety of injectable substances including cells, dermal fillers, drugs or biologics intradermally (dermis), subcutaneously (fat) or intramuscularly (muscle) via an array of needle configurations ranging from a single needle to a 16 needle configuration (4x4) on one head.  These interchangeable heads can be used to perform a variety of procedures, increase surface area coverage and speed-up procedure times.  

By relying on electrical power (instead of thumb pressure) and digital controls, RCI-02 automates and simplifies the injection process.  Equipped with a touch screen on its accompanying docking station, the device’s programmability allows for the delivery of precise quantities of material, at specific depths, through fine-gauge needles, on a single plain or trailing through multi-plains, as the needle retracts through the skin.
 
Overall benefits of this next-generation dermal injector technology are anticipated to include improved handling, reduction or elimination of the need for local anesthetic, quicker procedure times, improved patient experience, and a significant expansion of the areas that can be addressed with dermal fillers due to the ability to conduct broad, shallow and evenly-dispersed injections.

The near-term commercial opportunity for RCI-02 is to improve the injection of hyaluronic acid-based dermal fillers. RepliCel’s dermatologist advisors believe this device has the potential to significantly expand the number of HA dermal injection procedures currently performed. As an example, the HA market in the United States is currently valued at over US$1 billion per year and is growing at near double digits.2 These HA injections primarily address deep facial wrinkles and folds, but do not adequately address fine wrinkles. A device, such as RCI-02, which is capable of delivering a controlled injectable, utilizing a multi-head configuration, and eliminating the need for local anesthetic, has the potential to dramatically increase the HA market into new areas including fine wrinkles of the face, the hands and the décolleté.

About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the company believes is approximately one in three Americans, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration.   These conditions, often associated with aging, are caused by a deficit of healthy cells required for normal tissue healing and function. The Company’s product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is currently being co-developed with and under exclusive license by Shiseido for certain Asian countries. All product candidates are based on RepliCel’s innovative technology, utilizing cell populations isolated from a patient’s healthy hair follicles. RepliCel has also developed a proprietary injection device RCI-02, optimized for the administration of its products and licensable for use with other dermatology applications. Please visit http://www.replicel.com/ for additional information.

For more information, please contact:
Lee Buckler, CEO and President
Telephone: 604-248-8693 / lee@replicel.com

References:
1, 2 American Society of Plastic Surgeons (ASPS) Report of 2016 Surgeon/Physician Fees (April 2017) [Press release]. Retrieved from https://www.plasticsurgery.org/news/...nt-on-cosmetic-plastic-surgery




 

...es kommt Bewegung ins Spiel - schauen wir mal wer dieses Jahr noch an Bord springt für die weitere Entwicklung der in der Pipeline befindlichen Produkte. :-)  

Why RepliCel may be the most compelling biotech company to watch in Canada

http://www.bnn.ca/video/...biotech-company-to-watch-in-canada~1176636  

Weiß jemand warum es auf einmal aufwärts geht? Könnte keine News finden.  

https://replicel.com/20180116/